J&J’s combination extends lives of cancer patients versus rival drug
Johnson & Johnson’s combination therapy for treating a certain form of cancer without chemotherapy, has been shown to extend patients' lives by more.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Johnson & Johnson’s combination therapy for treating a certain form of cancer without chemotherapy, has been shown to extend patients' lives by more.
Danish pharmaceutical company Novo Nordisk’s combination drug achieved a 22.7% weight-loss reduction compared to a dummy drug during end-stage trials, according to a.
British-Swedish AstraZeneca signed a $1.92 billion licensing agreement with CSPC Pharmaceutical Group to develop, manufacture and commercialize a compound to treat a metabolic.